Sanofi-Aventis De Mexico
🚨 Critical Risk
FEI: 3008274551 • Ocoyoacac • MEXICO
FEI Number
3008274551
Location
Ocoyoacac
Country
MEXICOAddress
Acueducto Del Alto Lerma No 2, , Ocoyoacac, , Mexico
Critical Risk
FDA Import Risk Assessment
This firm has an extensive history of FDA import refusals with severe violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
NO ENGLISH
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).
DE/RX KIT
The article appears to be a combination medical device/prescription drug kit for which the prescription drug component was manufactured in the U.S., is offered for import by other than the manufacturer, and reimportation does not appear to have been authorized by the Secretary for use in a medical emergency.
NO ENGLISH
Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 12/22/2025 | 61KCL46SCOPOLAMINE HYDROBROMIDE (ANTI-CHOLINERGIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/18/2025 | 62UDA11DEXTROMETHORPHAN HYDROBROMIDE (ANTI-TUSSIVE/COLD) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/3/2025 | 64BDA24FUROSEMIDE (DIURETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/21/2025 | 60LDA01ACETAMINOPHEN (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/6/2024 | 60LDY21DIPYRONE (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/27/2024 | 54AGA13VITAMIN C (ASCORBIC ACID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/29/2024 | 62GDY46KETOPROFEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/17/2024 | 62LCY29HYDROXYCHLOROQUINE SULFATE (ANTI-PROTOZOAL, A-LEISHMANIAL, A-MALARIAL) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/8/2024 | 61HAL99ANTI-BACTERIAL, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/4/2023 | 64LAY03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/17/2023 | 66VCY99MISCELLANEOUS PATENT MEDICINES, ETC. | Division of Southeast Imports (DSEI) | |
| 8/23/2023 | 64BDA24FUROSEMIDE (DIURETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/17/2022 | 61ICH99ANTI-BACTERIAL ENZYME, N.E.C. | Division of Southeast Imports (DSEI) | |
| 10/5/2022 | 54YEY99VITAMIN, MINERAL, PROTEINS AND UNCONVENTIONAL DIETARY SPECIALITIES FOR HUMANS AND ANIMALS, N.E.C. | 324NO ENGLISH | Division of Southeast Imports (DSEI) |
| 10/5/2022 | 54YEY99VITAMIN, MINERAL, PROTEINS AND UNCONVENTIONAL DIETARY SPECIALITIES FOR HUMANS AND ANIMALS, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/15/2022 | 66VDY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/12/2022 | 66VCY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/4/2022 | 64LAY99GLUCOCORTICOID N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/21/2022 | 61LDA38CLOPIDOGREL BISULFATE (ANTI-COAGULANT) | Division of Southeast Imports (DSEI) | |
| 7/20/2022 | 60LCY21DIPYRONE (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/15/2022 | 62FCA17HYDROGEN PEROXIDE (SOL) (ANTI-INFECTIVE, TOPICAL) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/2/2022 | 61KDY16DICYCLOMINE HCL (ANTI-CHOLINERGIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/11/2022 | 66VCL99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/1/2022 | 62OCC05RAMIPRIL (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/13/2022 | 60LCY01ACETAMINOPHEN (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/2/2021 | 62GCY99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/5/2021 | 60QCA78PROPARACAINE HCL (ANESTHETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/28/2021 | 62CCB99ANTI-HYPERTENSIVE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/21/2021 | 61CDA99ANTI-ANEMIC, N.E.C. | 3340DE/RX KIT | Division of Southeast Imports (DSEI) |
| 3/31/2021 | 60LCA99ANALGESIC, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/1/2021 | 60LCA21DIPYRONE (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/10/2021 | 61LDY38CLOPIDOGREL BISULFATE (ANTI-COAGULANT) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/1/2021 | 60LCA21DIPYRONE (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/21/2020 | 60LCL99ANALGESIC, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/25/2020 | 60LDA21DIPYRONE (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/23/2020 | 62LDY29HYDROXYCHLOROQUINE SULFATE (ANTI-PROTOZOAL, A-LEISHMANIAL, A-MALARIAL) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/30/2019 | 62GDL99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/16/2019 | 56IDY76AZITHROMYCIN (MACAROLIDES) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/16/2019 | 60SDL14MAGNESIUM HYDROXIDE (ANTACID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/29/2019 | 64LCY99GLUCOCORTICOID N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/16/2019 | 62ODA41LOSARTAN POTASSIUM (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/12/2018 | 66VDK99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/24/2017 | 62BCY12MEZLOCILLIN SODIUM MONOHYDRATE (ANTI-HYPERLIPIDEMIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/10/2017 | 60SDL99ANTACID, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/10/2017 | 64MCA01CLOMIPHENE CITRATE (GONAD-STIMULATING PRINCIPLE) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 2/8/2017 | 60LCA01ACETAMINOPHEN (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/3/2017 | 60LCA01ACETAMINOPHEN (ANALGESIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 2/3/2017 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/25/2017 | 62GDL99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 11/28/2016 | 60LDA99ANALGESIC, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/25/2016 | 61PCY17INSULIN (INJ) (ANTI-DIABETIC) | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 5/25/2016 | 61PCY17INSULIN (INJ) (ANTI-DIABETIC) | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 4/5/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 4/5/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 4/5/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 4/5/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 4/5/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 4/5/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 4/5/2016 | 66VCA99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 4/1/2016 | 66VCA99MISCELLANEOUS PATENT MEDICINES, ETC. | Florida District Office (FLA-DO) | |
| 4/1/2016 | 66VCA99MISCELLANEOUS PATENT MEDICINES, ETC. | Florida District Office (FLA-DO) | |
| 4/1/2016 | 66VCA99MISCELLANEOUS PATENT MEDICINES, ETC. | Florida District Office (FLA-DO) | |
| 4/1/2016 | 66VCA99MISCELLANEOUS PATENT MEDICINES, ETC. | Florida District Office (FLA-DO) | |
| 4/1/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 3/15/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/15/2016 | 54YBA99VITAMIN, MINERAL, PROTEINS AND UNCONVENTIONAL DIETARY SPECIALITIES FOR HUMANS AND ANIMALS, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/15/2016 | 62LDY40METRONIDAZOLE (ANTI-PROTOZOAL, A-LEISHMANIAL, A-MALARIAL) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/19/2012 | 61HCB43LEVOFLOXACIN (ANTI-BACTERIAL, PART III) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/15/2012 | 62LCA40METRONIDAZOLE (ANTI-PROTOZOAL, A-LEISHMANIAL, A-MALARIAL) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/30/2012 | 64BCB24FUROSEMIDE (DIURETIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/7/2011 | 62LCA29HYDROXYCHLOROQUINE SULFATE (ANTI-PROTOZOAL, A-LEISHMANIAL, A-MALARIAL) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/7/2011 | 60LCB82PHENAZOPYRIDINE HCL (ANALGESIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/7/2011 | 66VCA99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 11/14/2011 | 60LCB82PHENAZOPYRIDINE HCL (ANALGESIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 2/24/2011 | 61GDA04NALIDIXIC ACID (ANTI-BACTERIAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 4/24/2009 | 60XCB17ATENOLOL (ANTI-ADRENERGIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 4/24/2009 | 62OCB05RAMIPRIL (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 7/31/2008 | 61WBJ03CICLOPIROX OLAMINE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 118NOT LISTED | Southwest Import District Office (SWI-DO) |
| 7/30/2008 | 61WBR39UNDECYLENIC ACID (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 118NOT LISTED | Southwest Import District Office (SWI-DO) |
| 7/30/2008 | 61WBJ03CICLOPIROX OLAMINE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 118NOT LISTED | Southwest Import District Office (SWI-DO) |
| 7/30/2008 | 54ACL01VITAMIN A | 118NOT LISTED | Southwest Import District Office (SWI-DO) |
| 1/18/2007 | 56GBR99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 1/18/2007 | 56GBR99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 1/18/2007 | 56GBJ99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 1/18/2007 | 56GBJ99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 1/18/2007 | 56GBJ99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 2/6/2006 | 56GBR99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 2/6/2006 | 56GBJ99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 2/6/2006 | 56GBJ99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 2/6/2006 | 56GBJ99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 6/7/2005 | 66VDY99MISCELLANEOUS PATENT MEDICINES, ETC. | Division of Southeast Imports (DSEI) | |
| 10/22/2002 | 60LCA21DIPYRONE (ANALGESIC) | 75UNAPPROVED | Chicago District Office (CHI-DO) |
| 10/22/2002 | 64ADJ20TRICLOSAN (DISINFECTANT) | 75UNAPPROVED | Chicago District Office (CHI-DO) |
Frequently Asked Questions
What is Sanofi-Aventis De Mexico's FDA import refusal history?
Sanofi-Aventis De Mexico (FEI: 3008274551) has 93 FDA import refusal record(s) in our database, spanning from 10/22/2002 to 12/22/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Sanofi-Aventis De Mexico's FEI number is 3008274551.
What types of violations has Sanofi-Aventis De Mexico received?
Sanofi-Aventis De Mexico has been cited for 6 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Sanofi-Aventis De Mexico come from?
All FDA import refusal data for Sanofi-Aventis De Mexico is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.